Systemic immune-inflammation index is associated with increased carotid intima-media thickness in hypertensive patients

Çırakoğlu, Ömer Faruk; Yılmaz, Ahmet

doi:10.1080/10641963.2021.1916944

Cited by 40 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is known that NLR values increase in acute pancreatitis [ 31 ], cardiac events [ 32 ], and atherosclerosis [ 33 ]. As a marker of systemic inflammation, NLR can also be considered as a potential prognostic factor for different tumors.…”

Section: Discussionmentioning

confidence: 99%

Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

Song

Zhang

Yin

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Inflammatory markers are associated with tumor genesis and progression, but their prognostic significance in osteosarcoma remains unclear. Therefore, we discussed the prognostic value of related inflammatory markers in osteosarcoma through a meta-analysis and systematic review. These inflammatory markers include C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), and Glasgow prognostic score (GPS). Methods. The Chinese National Knowledge Infrastructure (CNKI), Wanfang, Chinese Scientific Journals (VIP), PubMed, Embase, and Cochrane libraries were searched. The design of meta-analysis was made based on the PICOS (population, intervention/exposure, control, outcomes, and study design) principles, and STATA 15.1 was used to analyze the data. The Newcastle-Ottawa scale (NOS) was used to assess the quality of included studies. Hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DPS) were extracted for the investigation of the prognostic value of inflammatory markers. Results. Twelve researches with 2162 osteosarcoma patients were included in total. The pooled results showed that elevated NLR, CRP, and GPS are all greatly related to shortening of OS among patients with osteosarcoma ( HR = 1.68 , P = 0.007 , 95% CI: 1.15-2.45; HR = 1.96 , P = 0.002 , 95% CI: 1.28-3.00; HR = 2.54 , P < 0.0001 , 95% CI: 1.95-3.31, respectively), and CRP level is significantly associated with shortening of DPS among patients with osteosarcoma ( HR = 2.76 , 95% CI:2.01-3.80, P < 0.0001 ), additionally. However, the correlation between LMR or PLR and the prognosis of osteosarcoma is not statistically significant ( HR = 0.60 , 95% CI: 0.30-1.18, P = 0.138 ; HR = 1.13 , 95% CI: 0.85-1.49, P = 0.405 , respectively). The outcomes of subgroup analysis to NLR and CRP suggested that histology, ethnicity, metastasis, and sample size all have an impact on its prognosis of patients with osteosarcoma. Conclusion. Worsened prognosis may be related to high levels of NLR, CRP, and GPS before treatment rather than LMR or PLR, which can provide the basis for clinicians to judge the outcomes of prognosis. Trial Registration. PROSPERO (CRD42021249954), https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=249954.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

Song

Zhang

Yin

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that SII is a potential indicator for clinical endpoints for patients with coronary artery disease (13,14). The same was found in patients with hypertension (15), acute ischemic stroke (17), and chronic HF (27). However, no previous study has discussed the predictive value of SII in HCM.…”

Section: Discussionmentioning

confidence: 84%

“…Also, several studies indicated that markers of inflammation predicted adverse outcomes in HCM, such as high-sensitivity C reactive protein (CRP) ( 7 ), monocyte to high density lipoprotein cholesterol ratio (M/HDL-C) ( 8 ), and neutrophil to lymphocyte ratio (NLR) ( 10 ). A novel immune and inflammation index, namely, systemic immune-inflammation index (SII), which is calculated from platelet, neutrophil, and lymphocyte counts, has been examined as a prognostic factor for clinical outcomes in cancer patients ( 11 – 12 ) and in patients with cardiovascular diseases, such as coronary artery disease ( 13 – 14 ), hypertension ( 15 ), pulmonary embolism ( 16 ), and acute ischemic stroke ( 17 ). However, to date, the predictive ability of SII for mortality has not been reported in HCM.…”

Section: Introductionmentioning

confidence: 99%

Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy

Wang

Ruan

et al. 2021

ujms

View full text Add to dashboard Cite

Background: This study investigates the predictive value of the systemic immune-inflammation index (SII), which was calculated as platelet × neutrophil/lymphocyte ratio, for all-cause mortality in patients with hypertrophic cardiomyopathy (HCM). Methods: A total of 360 HCM patients were enrolled. They were divided into three groups based on the tertiles of baseline SII. The association between SII and all-cause mortality was analyzed. Results: There were 53 HCM patients who died during a mean follow-up time of 4.8 years (min: 6 days and max: 10.8 years), and the mortality rate was 3.0 per 100 person years. The cumulative mortality rate was significantly different among the three tertiles of SII (P = 0.004), and the mortality rate in tertile 3 was much higher than that in the first two tertiles. In reference to tertile 1, the fully adjusted hazard ratios of all-cause mortality were 1.02 for the tertile 2 (95% confidence interval [CI]: 0.45–2.31, P = 0.966) and 2.31 for tertile 3 (95% CI: 1.10–4.87, P = 0.027). No significant interactions between SII and other variables were observed during subgroup analysis. The discriminative power was better for mid-term outcome than that for short-term or long-term outcomes. Sensitivity analyses including patients with normal platelet and white blood cell count have revealed similar results. Conclusion: SII was a significant risk factor for all-cause mortality in HCM patients. However, the discriminative power was poor to moderate. It could be used in combination with other risk factors in mortality risk stratification in HCM.

show abstract

“…The few studies exploring the association between NLR and cIMT reported conflicting results. [22][23][24][25][26][27][28][29] Accordingly, some of them found an independent association between NLR and cIMT, [22][23][24][25][26] whereas this association was not observed in other studies. [27][28][29] Also, in a retrospective study, in patients with ischemic stroke, NRL was found to be a significant predictor of the cIMT in men but not in women.…”

Section: Discussionmentioning

confidence: 99%

“…A direct cross‐sectional association between NLR and carotid intima‐media thickness (cIMT) has been found in different studies 22–26 . However, this relationship has not been always confirmed 23,27–29 .…”

Section: Introductionmentioning

confidence: 99%

Neutrophil to lymphocyte ratio is not related to carotid atherosclerosis progression and cardiovascular events in the primary prevention of cardiovascular disease: Results from the IMPROVE study

et al. 2021

View full text Add to dashboard Cite

show abstract

Systemic immune-inflammation index is associated with increased carotid intima-media thickness in hypertensive patients

Cited by 40 publications

References 30 publications

Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy

Neutrophil to lymphocyte ratio is not related to carotid atherosclerosis progression and cardiovascular events in the primary prevention of cardiovascular disease: Results from the IMPROVE study

Contact Info

Product

Resources

About